Bladder Cancer VL

Improving Research and Clinical Care, Bladder Cancer in Women - Jean Hoffman-Censits

Details
Medical Oncologist and co-leader of the Women's Bladder Cancer Program at John Hopkins, Jean Hoffman-Censits joins Alicia Morgans to speak about bladder cancer in women and the initiatives and importance of the Women's Bladder Cancer Program. In many cases, there are significant delays in diagnosing bladder cancer in women. Dr. Hoffman-Censits discusses the continuous narrative of the delay in dia...

Current and Emerging Therapies for Non-Muscle Invasive Bladder Cancer after BCG - Chris Wallis & Zach Klaassen

Details
For this Journal Club, Christopher Wallis, MD, and Zach Klasseen, MD discuss a recently published meta-analysis on treatment options for patients with non-muscle invasive bladder cancer unresponsive or refractory to BCG therapy. They provide context for this review and discuss the clinical relevance of managing the risk of recurrence in NMIBC. Biographies: Zachary Klaassen, MD, MSc, Urologic Oncol...

Phase III Nadofaragene Firadenovec for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Joshua J. Meeks

Details
In this discussion, Josh Meeks joins Alicia Morgans to review the new advances phase III Nadofaragene Firadenovec (Adstiladrin®) trial for BCG unresponsive non-muscle invasive bladder cancer patients. Dr. Meeks details the results of this recently presented trial data and why he believes this is the beginning of the next era in treating these patients. Biographies: Josh J. Meeks, MD, Ph.D., Assist...

Research and Clinical Practice Strategies Due to the BCG Shortage - Sam S. Chang

Details
Sam Chang joins Ashish Kamat to discuss strategies for clinical trials and patient selection required in the face of the world-wide shortage of BCG. Biographies: Sam S. Chang, MD, MBA , Patricia and Rodes Hart Endowed Chair of Urologic Surgery Professor Department of Urology at Vanderbilt University Medical Center, Department of Urology Ashish Kamat, MD, MBBS Professor of Urology and Wayne B. Dudd...

Bladder Cancer Research That Impacts Urology Clinical Practice - Josh Meeks

Details
Joshua Meeks joins Ashish Kamat in discussing the most recent relevant research papers in bladder cancer. Together they explore the publications on checkpoint inhibitors, the use of The Cancer Genome Atlas, Enhanced Recovery after Cystectomy and the impact of blue light flexible cystoscopy with CYSVIEW. Biographies: Josh J. Meeks, MD, Ph.D., Assistant Professor of Urology and Biochemistry and Mole...

The Benefits of Early Recovery After Radical Cystectomy (ERAS) Protocols - Sima Porten

Details
Sima Porten joins Ashish Kamat in a conversation regarding post-operative care of radical cystectomy patients. As someone who has first-hand experience in the difficulty of a culture shift in this process, Dr. Porten outlines how clinics can successfully adopt the ERAS protocol for radical cystectomy, emphasizing the importance of its effectiveness driving a team mentality in the clinical setting....

The BCG Shortage - What To Do In This Setting - Joshua Meeks

Details
Alicia Morgans and Joshua Meeks discuss the current shortage of Bacille Calmette-Guérin (BCG) and how it is impacting clinicians' treatment decisions and ongoing clinical trials. Dr. Meeks shares his thoughts behind the shortage and provides his strategy for clinicians and teams to make the proper patient selection to use the available BCG effectively to cover as many patients as possible. Biograp...

Advancements in BCG Unresponsive Bladder Cancer: Highlights from the 2019 SUO Meeting - Joshua Meeks

Details
Alicia Morgans and Joshua Meeks discuss the recent advancements in treating Bacille Calmette-Guérin (BCG) unresponsive bladder cancer that came from the 2019 meeting of the Society of Urologic Oncology. They review the many promising clinical trials including some early data from the Phase III VICINIUM trial as well as a promising combination intravesical chemotherapy options for non-muscle-invasi...

A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar

Details
Arjun Balar and Alicia Morgans discuss the new era in systemic therapies in non-muscle invasive bladder cancer (NMIBC) focusing on the systemic checkpoint inhibitor, pembrolizumab that resulted in the US FDA approval of pembrolizumab for treatment in early bladder cancer. Historically being in the domain of urologic oncologists, Drs. Morgans and Balar discuss the importance of the medical oncologi...

Utilizing Change Management for Successful Implementation of Blue light cystoscopy (BLC™) - Rebecca Roe

Details
Rebecca Roe speaks to an interdisciplinary approach to implementation of Blue Light Cystoscopy (BLC™) in her community hospital center, giving a Clinical Education Program Coordinator's perspective. Her team engaged in the five management practices looking at ongoing communication and clinical training and measured things along the way, seeking feedback from every discipline that was utilized, whe...